Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s12094-017-1715-1
Published Online: 2017-08-07
Published Print: 2018-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zheng, H.
Xie, L.
Zhan, M.
Wen, F.
Xu, T. http://orcid.org/0000-0002-4239-4170
Li, Q.
License valid from 2017-08-07